# US 2012/0252895 A1 · Therapeutic methods employing nitric oxide precursors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252895 A1
- Document ID: US20120252895A1
- Status: Published application
- Kind: A1
- Application number: 13/456,014
- Filed: 2012-04-25
- Published: 2012-10-04
- Earliest claimed: 1999-06-01
- Assignees: Vanderbilt University
- Inventors: Marshall L. Summar; Brian W. Christman; Frederick E. Barr
- Web page: https://patentgrep.com/patent/US20120252895A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 9/93: {Ligases (6)}
- C12Y 603/04016: Carbamoyl-phosphate synthase (ammonia) (6.3.4.16)
- C12Y 603/05005: Carbamoyl-phosphate synthase (glutamine-hydrolysing) (6.3.5.5)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A method of treating a mammal subjected to cardiac surgery comprising intravenously administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising citrulline.

### Claim 35 (depends on 34)

The method of claim 34, wherein the mammal is human.

### Claim 36

The method of 34, wherein the mammal comprises a sub-optimal urea cycle function.

### Claim 37 (depends on 36)

The method of claim 36, wherein the sub-optimal urea cycle function is associated with decreased citrulline levels.

### Claim 38 (depends on 34)

The method of claim 34, wherein the mammal comprises a CPSI polymorphism.

### Claim 39 (depends on 34)

The method of claim 34, further comprising detecting the presence of a CPSI polymorphism.

### Claim 40 (depends on 34)

The method of claim 34, wherein the citrulline is administered at a dose ranging from about 100 mg to about 30,000 mg.

### Claim 41 (depends on 34)

The method of claim 34, wherein the citrulline is administered at a dose ranging from about 250 mg to about 1,000 mg.

### Claim 42 (depends on 34)

The method of claim 34, wherein the cardiac surgery comprises correcting defects associated with excess pulmonary blood flow.

### Claim 43 (depends on 34)

The method of claim 34, wherein the defects are selected from atrioventricular septal defect, large unrestrictive ventricular septal defect, or combinations thereof.

### Claim 44 (depends on 34)

The method of claims 34, wherein the cardiac surgery includes a procedure selected from cardiopulmonary bypass, bidirectional Glenn and Modified Fontan procedures, Norwood procedures, arterial switch procedures, or combinations thereof.

### Claim 45 (depends on 34)

The method of claim 34, wherein the pharmaceutical composition maintains a low post-operative pulmonary vascular tone in the mammal after surgical repair of a congenital heart defect.

### Claim 46 (depends on 35)

The method of claim 35, wherein post-operative pulmonary blood flow is entirely passive.

### Claim 47 (depends on 35)

The method of claim 35, wherein the congenital heart defect is a result of excess pulmonary blood flow.

### Claim 48 (depends on 37)

The method of claim 37, wherein the excess pulmonary blood flow is associated with a cardiac defect selected from atrioventricular septal defect, large unrestrictive ventricular septal defect, or combinations thereof.

### Claim 49 (depends on 34)

The method of claim 34, wherein the surgery includes cardiopulmonary bypass.

### Claim 50 (depends on 34)

The method of claim 34, wherein the composition is suitable for administering pre-operative, peri-operative, and/or post-operative to the surgery.

### Claim 51 (depends on 34)

The method of claim 34, wherein the composition is administered approximately 30 minutes before and/or every 12 hours pre-operative to the surgery.

### Claim 52 (depends on 34)

The method of claim 34, wherein the citrulline is administered over a post-operative period every 12 hours after the surgery.

### Claim 53 (depends on 34)

The method of claim 34, wherein the citrulline is administered one or more times during a peri-operative period.

### Claim 54 (depends on 34)

The method of claim 34, wherein the citrulline is administered one or more times during a post-operative period.

### Claim 55 (depends on 34)

The method of claim 34, wherein upon administration the composition prevents any elevation in post-operative pulmonary vascular tone.

### Claim 56 (depends on 34)

The method of claim 34, wherein upon administration the composition prevents a post-operative decrease in pulmonary blood flow and/or fall in cardiac output.

### Claim 57 (depends on 34)

The method of claim 34, wherein upon administration the composition prevents an outcome of persistent pleural effusion, prolonged requirement for peural or mediastinal drainage tubes, prolonged ventilation, prolonged intensive care unit stays, or combinations thereof.

### Claim 58 (depends on 34)

The method of claim 34, wherein citrulline is administered at a dose of 3.8 g/m2/day.
